Discovery & Development Summit Asia 2025 is Global Engage’s inaugural platform that brings together the Drug Discovery & Development, Nucleic Acid Therapeutics and Precision Medicine congresses. This summit allows the exploration of the full spectrum of therapeutic innovation, from early-stage discovery to clinical translation and commercialization. Attendees will gain insights into assay development, screening technologies,…
Personalized medicine is rapidly becoming a cornerstone of modern healthcare, promising to redefine how treatments are tailored to individual patients. Unlike traditional approaches, which often rely on a one-size-fits-all model, personalized medicine uses detailed information about a person’s genetic makeup, lifestyle, and environment to create more effective and precise treatments. This approach is gaining traction…
Shots:
PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, and China. This month’s report includes 10 biological drugs, 15 small molecules, 5 cell and gene therapies, 4 devices, 1 vaccine and 1 microbiota
MicuRx’ Contezolid and Contezolid acefosamil, focused on the treatment of Diabetic…
Shots:
With more than 50% of ongoing clinical trials worldwide in oncology domains, cancer remains one of the leading causes of death worldwide. Oncology companies are steadfastly looking for innovative therapies to cure both hematologic and solid tumor cancer
The global oncology drug market size in 2022 was valued at $185B and is forecasted to…
“The supreme art of war is to subdue the enemy without fighting” – Sun Zhu, Competitive Intelligence benefits your organization gather and analyzing information related to your competitor’s business models. This deep analysis helps your organization reduce the strategic risks and increase revenue opportunities by attaining deep insights into how the market has changed and…
In an interview with PharmaShots, Ray Lee, CEO at Teclison shared his views on the completion of a $5.9 million capital raise and advancement of its oncology drug portfolio
Shots:
Ray spoke about Teclison’s recently completed funding of $5.9 million led by W.T.T. Investment
He focused on the development of the lead candidate in the…

